Neuroscience

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

New DDW Highlights episode live now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have heard about a number of studies that demonstrate an inventive… Read More

#News

#Allergy #Alzheimer's #Antibodies #Artificial intelligence (AI) #Autism #Cancer drug targets #Cancer research #Drug development #Influenza #Microbiome #Monoclonal antibodies

This week in drug discovery (26-30 June)  

News round-up for 26-30 June by DDW Digital Content Editor Diana Spencer. This week we have heard about a number of studies that demonstrate an inventive solution to an old problem, either through the use of an original approach or new, advanced technology. Whether… Read More

#News

Neurons in a brain with Alzheimer's disease
#AC Immune #Alzheimer's #FDA #Immunotherapy #Neurodegenerative disorders

FDA fast-tracks immunotherapy for Alzheimer’s disease

AC Immune has received Fast Track designation from the US Food and Drug Administration (FDA) for its anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer’s disease (AD). This follows FDA clearance of the Investigational New Drug (IND) application enabling expansion to the USA of the ongoing Phase… Read More

#Editor's Choice #News #Regulatory

Mental health
#Antidepressants #Anxiety disorder #Depression #Drug discovery #Mental health #Neuroscience #Psychiatry

World Wellbeing Week 2023: Celebrating drug discovery innovation

DDW’s Diana Spencer provides an overview of the latest innovations in drug discovery for mental health. World Wellbeing Week was created to celebrate the many aspects of wellbeing, from meaningful, purposeful work to financial security, physical, mental and emotional health, social resilience and empathic corporate and civic leadership, community relations… Read More

#Exclusive Content

#Alchemab Therapeutics #Alzheimer's #Antibodies #Therapeutics

Alchemab unveils newly discovered Alzheimer’s candidate 

Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate.   The data was announced at the Antibody Industrial Symposium in Tours, France, June 22-23, 2023.  ATLX-1088 is a potential… Read More

#News

AI brain partnership
#ACROBiosystems #Diagnostics #Electrophysiology #In vivo #Neuroscience #Partnership

Partnership to accelerate neuroscience drug discovery  

ACROBiosystems, through ACRO Certify and under its Aneuro brand, has launched in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips.   Together, the two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialisation.  Electrophysiology is a critical part… Read More

#News

#FDA #Minoryx Therapeutics #Neurodegenerative disorders #Phase III trial #Rare disease

FDA approves Phase III cerebral Adrenoleukodystrophy trial

The US Food and Drug Administration (FDA) has approved Minoryx Therapeutics’ Phase III clinical trial (CALYX) of leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD). Patient recruitment is expected to start by the end of Q2 2023 with results anticipated by late 2025. Marc Martinell,… Read More

#News #Regulatory

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Axol Bioscience #Neuroscience #Stem cells #StrataStem

A step closer to ‘clinical trial in a dish’ for Alzheimer’s  

Axol Bioscience has signed an exclusive agreement with StrataStem to access and commercialise its collection of Alzheimer’s Disease (AD) patient samples.   Harnessing its stem cell expertise, Axol will reprogramme these patient samples into induced Pluripotent Stem Cells (iPSCs) that can then be differentiated into a range… Read More

#News

AI brain partnership
#AI #Drug discovery #Innovation #Mental health #Partnership

Partnership targets hard-to-diagnose mental health conditions 

Pangaea Data has been awarded a strategic partnership by the newly established Mental Health Research for Innovation Centre (M-RIC).   Pangaea is a provider of a novel artificial intelligence (AI)-driven product for characterising patients by automatically discovering clinical signatures for 4,000 hard-to-diagnose conditions in an evolving, privacy-preserving and… Read More

#News

#AI #ALS #BenevolentAI #Drug discovery

BenevolentAI progresses drug for the potential treatment of ALS 

BenevolentAI, developers of AI that accelerates biopharma discovery, has delivered BEN-34712, its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS).  BEN-34712 is an oral, potent and selective brain penetrant RARɑ𝛃 (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug… Read More

#News

Neurons in the brain
#Algiax Pharmaceuticals #Neurology #Neuroscience #Painkillers #Phase II trial #Trial data

Phase IIa trial expanded for promising neuropathic pain drug

The independent Data Monitoring Committee (DMC) has recommended the continuation of Algiax Pharmaceuticals’ Phase IIa study with lead candidate AP-325 in chronic neuropathic pain. Based on the positive DMC review and confirmed financial commitment from its investors, the company will expand the trial to Belgium, France,… Read More

#News

#Alzheimer's #Antibody #Eisai #MHRA #Neurodegenerative disorders #Phase II trial

Eisai applies for MHRA approval for lecanemab in Alzheimer’s

Eisai has submitted a marketing authorisation application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody to the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. The MAA is for the treatment of early Alzheimer’s disease (AD) (mild cognitive impairment due to AD and mild AD dementia)… Read More

#News #Regulatory

#ALS #LifeArc #Neuroscience #Partnership #Precision medicine #PrecisionLife

Partners to advance precision medicines for MND

Not-for-profit medical research organisation LifeArc and techbio company PrecisionLife have agreed a strategic R&D collaboration to accelerate the discovery of targeted treatments for motor neurone disease (MND). MND is also known as amyotrophic lateral sclerosis (ALS) and Lou Gehrig’s disease. The collaboration will accelerate… Read More

#News

Neurons
#AAV #Genetics / genomics #High throughput screening #Neuroscience #Sania Therapeutics #University College London

Start-up will focus on medicines for neural circuit dysfunction

Sania Therapeutics, a new company focused on developing genetic medicines for neural circuit dysfunction, has launched at the American Society of Gene & Cell Therapy (ASGCT) conference. The company’s approach combines adeno-associated viruses (AAV) in human neural circuits with tuneable conditionally-activated ion channels. This corrects dysfunctional neural excitation. Sania’s technology… Read More

#Business & Investment #News

Esther Sammler
#Biogen #Clinical trial #Denali Therapeutics #Neurodegenerative disorders #Parkinson's #University of Dundee

New trial will investigate LRRK2 inhibitors for Parkinson’s

A study that could lead to the development of new treatments for Parkinson’s disease has launched at the University of Dundee, Scotland. The study is utilising LRRK2 inhibitors developed by Denali Therapeutics and Biogen. Mutations in the LRRK2 protein kinase are the most frequent cause of… Read More

#Editor's Choice #News

Doctor examining brain MRI
#FSD Pharma #Lucid Psycheceuticals #Multiple sclerosis #Neuroscience #Phase I trial

New drug candidate for MS shows promise in Phase I trial

FSD Pharma has dosed the first cohort of patients in its Phase I clinical trial evaluating Lucid-MS for the treatment of multiple sclerosis (MS). “Our clinical development team and international advisory committee are delighted at the progress of this milestone and completing dosing the first cohort,”… Read More

#News